Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Pentobarbital sodium
Drug ID BADD_D01727
Description A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236)
Indications and Usage For the short-term treatment of insomnia.
Marketing Status approved; investigational; vet_approved
ATC Code N05CA01
DrugBank ID DB00312
KEGG ID D00500
MeSH ID D010424
PubChem ID 23676152
TTD Drug ID D0F0YZ
NDC Product Code 72735-010; 25021-676; 24201-010; 0792-0045; 76478-501; 0792-0044; 17478-181; 53834-601; 65392-0227
UNII NJJ0475N0S
Synonyms Pentobarbital | Pentobarbitone | Mebubarbital | Etaminal | Ethaminal | Sagatal | Nembutal | Pentobarbital Sodium | Pentobarbital, Monosodium Salt | Monosodium Salt Pentobarbital | Diabutal | Mebumal
Chemical Information
Molecular Formula C11H17N2NaO3
CAS Registry Number 57-33-0
SMILES CCCC(C)C1(C(=O)NC(=NC1=O)[O-])CC.[Na+]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Agitation19.06.02.001; 17.02.05.012--
Anaemia megaloblastic14.12.01.003; 01.03.02.003--Not Available
Angioedema10.01.05.009; 22.04.02.008; 23.04.01.001--Not Available
Anxiety19.06.02.002--
Apnoea22.02.01.001--
Ataxia17.02.02.001; 08.01.02.004--
Bradycardia02.03.02.002--Not Available
Confusional state17.02.03.005; 19.13.01.001--
Constipation07.02.02.001--
Depressed level of consciousness17.02.04.002--
Dermatitis exfoliative23.03.07.001; 10.01.01.004--
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Hallucination19.10.04.003--
Headache17.14.01.001--
Hyperkinesia17.01.02.008--Not Available
Hypersensitivity10.01.03.003--
Hypotension24.06.03.002--
Hypoventilation22.02.01.007--Not Available
Injection site reaction12.07.03.015; 08.02.03.014--
Insomnia19.02.01.002; 17.15.03.002--
Nausea07.01.07.001--
Nervousness19.06.02.003--Not Available
Nightmare19.02.03.003--Not Available
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Syncope02.11.04.015; 24.06.02.012; 17.02.04.008--
Thinking abnormal19.10.03.001; 17.02.05.023--Not Available
Vomiting07.01.07.003--
Mental disorder19.07.01.002--Not Available
The 1th Page    1 2    Next   Last    Total 2 Pages